Agomab director reports initial stock option stake

Agomab Therapeutics NV director Hammer Ohad has reported an initial equity position consisting of stock options.

Rhea-AI Filing Summary

Agomab Therapeutics NV director Hammer Ohad has reported an initial equity position consisting of stock options. These options allow him to buy up to 27,921 common shares at an exercise price of $14.2600 per share until January 15, 2036.

According to the vesting terms, 33% of the shares underlying this option will vest on February 9, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service. The common shares may be represented by American Depositary Shares, each currently representing one common share, and the exercise price reflects conversion from euros to U.S. dollars at a stated exchange rate.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hammer Ohad

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 27,921 contracts (Direct)

Footnotes (3)

1. F1. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. F2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
3. F3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Hammer Ohad’s Form 3 for Agomab Therapeutics (AGMB) report?

The Form 3 shows Hammer Ohad’s initial beneficial ownership via stock options in Agomab Therapeutics. He holds options to buy up to 27,921 common shares at a fixed exercise price, establishing his baseline equity position as a director.

How many Agomab Therapeutics shares are covered by Hammer Ohad’s options?

Hammer Ohad’s reported stock option grants cover up to 27,921 underlying common shares of Agomab Therapeutics. This figure represents his current option-based right to purchase shares, rather than common shares he already owns outright.

What is the exercise price of Hammer Ohad’s Agomab Therapeutics stock options?

The stock options have an exercise price of $14.2600 per underlying common share. This exercise price is reported in U.S. dollars and reflects a conversion from euros using an exchange rate specified as of March 16, 2026.

When do Hammer Ohad’s Agomab Therapeutics stock options vest?

For this option grant, 33% of the underlying shares vest on February 9, 2027. The remaining shares then vest in 24 equal monthly installments, provided Hammer Ohad continues to serve in his role throughout each vesting date.

When do Hammer Ohad’s Agomab Therapeutics stock options expire?

The reported stock options are scheduled to expire on January 15, 2036. After that expiration date, any unexercised portion of the options would lapse, and Hammer Ohad would no longer have the right to purchase those underlying shares.

How are Agomab Therapeutics common shares represented in this Form 3?

The filing notes that the company’s common shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one common share, so the option’s 27,921 underlying shares correspond to the same number of potential ADSs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hammer Ohad

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	01/15/2036	Common shares(2)	27,921	$14.26(3)	D

Explanation of Responses:

1. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)